JP2017514866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514866A5 JP2017514866A5 JP2016566754A JP2016566754A JP2017514866A5 JP 2017514866 A5 JP2017514866 A5 JP 2017514866A5 JP 2016566754 A JP2016566754 A JP 2016566754A JP 2016566754 A JP2016566754 A JP 2016566754A JP 2017514866 A5 JP2017514866 A5 JP 2017514866A5
- Authority
- JP
- Japan
- Prior art keywords
- dressing
- dressings
- nms
- wound
- registered trademark
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010052428 Wound Diseases 0.000 claims 13
- 208000027418 Wounds and injury Diseases 0.000 claims 13
- 229940125431 BRAF inhibitor Drugs 0.000 claims 9
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 9
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229960002465 dabrafenib Drugs 0.000 claims 6
- 229950001969 encorafenib Drugs 0.000 claims 6
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- MLSAQOINCGAULQ-QFMPWRQOSA-N (E)-SB-590885 Chemical compound C1=CC(OCCN(C)C)=CC=C1C1=NC(C=2C=CN=CC=2)=C(C=2C=C3CCC(/C3=CC=2)=N\O)N1 MLSAQOINCGAULQ-QFMPWRQOSA-N 0.000 claims 3
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 claims 3
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 3
- ZGBGPEDJXCYQPH-UHFFFAOYSA-N 3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxo-6-quinazolinyl)amino]phenyl]benzamide Chemical compound C1=C(NC=2C=C3C(=O)N(C)C=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(C)(C)C#N)=C1 ZGBGPEDJXCYQPH-UHFFFAOYSA-N 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 3
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 3
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims 3
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims 3
- -1 RO497655 Chemical compound 0.000 claims 3
- 229930003316 Vitamin D Natural products 0.000 claims 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 3
- 229940035676 analgesics Drugs 0.000 claims 3
- 229940069428 antacid Drugs 0.000 claims 3
- 239000003159 antacid agent Substances 0.000 claims 3
- 239000000730 antalgic agent Substances 0.000 claims 3
- 239000000645 desinfectant Substances 0.000 claims 3
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3r)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 239000000017 hydrogel Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- MMNNTJYFHUDSKL-UHFFFAOYSA-N methyl n-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1h-benzimidazol-2-yl]carbamate Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(C1=CC=CC=C1C1=O)(O)N1C1=CC(Cl)=CC=C1C MMNNTJYFHUDSKL-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229960003787 sorafenib Drugs 0.000 claims 3
- 229960000487 sorafenib tosylate Drugs 0.000 claims 3
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 claims 3
- 235000000346 sugar Nutrition 0.000 claims 3
- 150000008163 sugars Chemical class 0.000 claims 3
- 229940081616 tafinlar Drugs 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 229950005976 tivantinib Drugs 0.000 claims 3
- 229960004066 trametinib Drugs 0.000 claims 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 3
- 229960003862 vemurafenib Drugs 0.000 claims 3
- 235000019155 vitamin A Nutrition 0.000 claims 3
- 239000011719 vitamin A Substances 0.000 claims 3
- 235000019166 vitamin D Nutrition 0.000 claims 3
- 239000011710 vitamin D Substances 0.000 claims 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 3
- 229940046008 vitamin d Drugs 0.000 claims 3
- 229940034727 zelboraf Drugs 0.000 claims 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 230000002745 absorbent Effects 0.000 claims 2
- 239000002250 absorbent Substances 0.000 claims 2
- 229940072056 alginate Drugs 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 230000001851 biosynthetic effect Effects 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 239000000416 hydrocolloid Substances 0.000 claims 2
- 239000000565 sealant Substances 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989398P | 2014-05-06 | 2014-05-06 | |
| US61/989,398 | 2014-05-06 | ||
| PCT/US2015/029562 WO2015171833A1 (en) | 2014-05-06 | 2015-05-06 | Wound healing using braf inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514866A JP2017514866A (ja) | 2017-06-08 |
| JP2017514866A5 true JP2017514866A5 (https=) | 2018-06-21 |
Family
ID=54392978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566754A Pending JP2017514866A (ja) | 2014-05-06 | 2015-05-06 | Ｂｒａｆ阻害剤を使用する創傷治癒 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170100345A1 (https=) |
| EP (1) | EP3139927A4 (https=) |
| JP (1) | JP2017514866A (https=) |
| CN (1) | CN106535900A (https=) |
| WO (1) | WO2015171833A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017154001A1 (en) * | 2016-03-10 | 2017-09-14 | Lutris Pharma Ltd. | Use of braf inhibitors for treating cutaneous reactions |
| WO2017223245A1 (en) * | 2016-06-21 | 2017-12-28 | The Regents Of The University Of California | Wound healing using braf inhibitors |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| US11998550B2 (en) | 2017-04-20 | 2024-06-04 | Thomas Jefferson University | Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation |
| KR102328351B1 (ko) * | 2017-07-29 | 2021-11-19 | 루트리스 파마 엘티디. | 신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도 |
| MX2020001546A (es) * | 2017-08-08 | 2020-08-03 | Memorial Sloan Kettering Cancer Center | Uso de inhibidores de braf para tratar reacciones cutaneas causadas por el tratamiento con un inhibidor de mek. |
| JP7379355B2 (ja) * | 2017-11-20 | 2023-11-14 | トルレモ セラピューティクス アーゲー | 診断方法 |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| ES2952251T3 (es) * | 2019-02-12 | 2023-10-30 | Lutris Pharma Ltd | Uso de composiciones tópicas de inhibidores de BRaf para el tratamiento de la dermatitis por radiación |
| DE102019129444A1 (de) * | 2019-10-31 | 2021-05-06 | Lts Lohmann Therapie-Systeme Ag | Lagtime-Verkürzung/Eisspray |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977428A (en) * | 1996-12-20 | 1999-11-02 | Procyte Corporation | Absorbent hydrogel particles and use thereof in wound dressings |
| JP4263402B2 (ja) * | 2001-12-27 | 2009-05-13 | 三笠製薬株式会社 | 創傷治療用製剤 |
| MXPA04007832A (es) * | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| WO2005091891A2 (en) * | 2004-03-11 | 2005-10-06 | Kythera Biopharmaceuticals, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
| US20050214325A1 (en) * | 2004-03-26 | 2005-09-29 | Vvii Newco 2003, Inc. | Compositions and methods to increase the effect of a neurotoxin treatment |
| CN102206216B (zh) * | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| DE102005060461A1 (de) * | 2005-12-17 | 2007-07-12 | Paul Hartmann Ag | Medizinische Zusammensetzung |
| SI2947072T1 (sl) * | 2008-03-17 | 2017-03-31 | Ambit Biosciences Corporation | 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni |
| US20100222371A1 (en) * | 2008-11-20 | 2010-09-02 | Children's Medical Center Corporation | Prevention of surgical adhesions |
| JP2012524058A (ja) * | 2009-04-15 | 2012-10-11 | フォンダツィオーネ アイアールシーシーエス イスティトゥト ナツィオナーレ デイ トゥモリ | 血管透過性亢進の治療におけるマルチキナーゼ阻害剤の使用 |
| US9180127B2 (en) * | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| JP5871896B2 (ja) * | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂ−ｒａｆキナーゼインヒビター |
| US20120010229A1 (en) * | 2010-07-08 | 2012-01-12 | Macdougall John R | Therapeutic regimens for hedgehog-associated cancers |
| WO2012051204A2 (en) * | 2010-10-11 | 2012-04-19 | Purdue Research Foundation | Antimicrobial formulations that aid in wound healing |
| CA2818544A1 (en) * | 2010-11-19 | 2012-05-24 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment with braf inhibitor |
| EP2707508A4 (en) * | 2011-05-10 | 2015-07-29 | Brunangelo Falini | BIOMARKERS OF TRICHOLEUCOCYTE LEUKEMIA AND METHODS OF USE THEREOF |
| JP2015532272A (ja) * | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ |
| CN103520162B (zh) * | 2013-10-15 | 2015-11-18 | 中国科学院上海药物研究所 | 达拉菲尼抑制程序性坏死和保护肝脏的应用 |
-
2015
- 2015-05-06 US US15/309,190 patent/US20170100345A1/en not_active Abandoned
- 2015-05-06 JP JP2016566754A patent/JP2017514866A/ja active Pending
- 2015-05-06 CN CN201580036956.XA patent/CN106535900A/zh active Pending
- 2015-05-06 WO PCT/US2015/029562 patent/WO2015171833A1/en not_active Ceased
- 2015-05-06 EP EP15789274.6A patent/EP3139927A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514866A5 (https=) | ||
| Skórkowska-Telichowska et al. | The local treatment and available dressings designed for chronic wounds | |
| WO2011127188A3 (en) | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds | |
| ES2717276T3 (es) | Apósito con liberación controlada de agentes activos | |
| US20080020025A1 (en) | Composition for wound care and method of using same | |
| CN103143052A (zh) | 医用胶原敷料及其制备方法和用途 | |
| US20240261377A1 (en) | Use of clostridium histolyticum protease mixture in promoting wound healing | |
| JP2019511468A5 (https=) | ||
| CN105709273B (zh) | 一种含聚乙二醇的液体医用敷料 | |
| US10874555B2 (en) | Wound dressing | |
| RU2015148636A (ru) | Модуляция активности гепарин-связывающего эпидермального фактора роста для заживления барабанной перепонки | |
| CZ12015U1 (cs) | Přípravek pro prevenci adheze bandáľe na ránu | |
| WO2019078931A1 (en) | SARRASIN HONEY AND HEALING WELDING FOR BACITRACIN-BASED WAFER | |
| WO2019040185A1 (en) | SARRASIN HONEY AND HEALING WELDING FOR IODIZED POVIDONE WOUND | |
| Karri et al. | Understanding the implications of pharmaceutical excipients and additives in the treatment of diabetic foot ulcers | |
| JP2017537163A5 (https=) | ||
| ES2602179T3 (es) | Un dispositivo para el cuidado de heridas | |
| RU2526183C1 (ru) | Гемостатическая противоожоговая ранозаживляющая композиция | |
| Nagy et al. | Negative pressure wound therapy: an effective, minimally invasive therapeutic modality in burn wound management | |
| US11213564B2 (en) | Buckwheat honey and bacitracin wound-healing dressing | |
| WO2007143586A2 (en) | Composition for wound care and method of using same | |
| RU69398U1 (ru) | Пластырь | |
| WO2009158667A2 (en) | Povidone compositions for wound healing | |
| US20130045269A1 (en) | Formulations and methods for wound treatment | |
| CN103285418A (zh) | 基于大面积烧伤创面用的新型生物抗菌敷料气雾剂 |